These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7742183)

  • 1. Pharmacotherapy of obsessive-compulsive disorder.
    Ko SM
    Br J Clin Pract; 1995; 49(1):36-9. PubMed ID: 7742183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of the resistant obsessive-compulsive disorder: an update].
    Crespo Facorro B; Gomez-Hernández R
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(1):61-9. PubMed ID: 9133159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies.
    Jenike MA; Rauch SL
    J Clin Psychiatry; 1994 Mar; 55 Suppl():11-7. PubMed ID: 7915709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of treatment-refractory obsessive compulsive disorder patients.
    Dominguez RA; Mestre SM
    J Clin Psychiatry; 1994 Oct; 55 Suppl():86-92. PubMed ID: 7961537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for obsessive-compulsive disorder.
    Greist JH; Jefferson JW
    Br J Psychiatry Suppl; 1998; (35):64-70. PubMed ID: 9829028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological approaches to treatment-resistant obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Barr LC; Aronson SC; Price LH
    J Clin Psychiatry; 1993 Jun; 54 Suppl():16-26. PubMed ID: 8331098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
    Carpenter LL; McDougle CJ; Epperson CN; Price LH
    Drug Saf; 1996 Aug; 15(2):116-34. PubMed ID: 8884163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological management of treatment-resistant obsessive-compulsive disorder.
    Abudy A; Juven-Wetzler A; Zohar J
    CNS Drugs; 2011 Jul; 25(7):585-96. PubMed ID: 21699270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder.
    Hollander E
    J Clin Psychiatry; 1999; 60 Suppl 15():38-44. PubMed ID: 10418814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
    Poppe C; Müller ST; Greil W; Walder A; Grohmann R; Stübner S
    J Affect Disord; 2016 Aug; 200():89-96. PubMed ID: 27130958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current issues in the pharmacologic management of obsessive compulsive disorder.
    Rasmussen SA; Eisen JL; Pato MT
    J Clin Psychiatry; 1993 Jun; 54 Suppl():4-9. PubMed ID: 8101187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of borderline personality disorder.
    Hirschfeld RM
    J Clin Psychiatry; 1997; 58 Suppl 14():48-52; discussion 53. PubMed ID: 9418746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacotherapy of obsessive-compulsive disorder.
    McDougle CJ; Goodman WK; Price LH
    Pharmacopsychiatry; 1993 May; 26 Suppl 1():24-9. PubMed ID: 8378419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
    Ramasubbu R
    Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
    [No Abstract]   [Full Text] [Related]  

  • 17. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
    Sahraian A; Bigdeli M; Ghanizadeh A; Akhondzadeh S
    J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurobiological models of obsessive-compulsive disorder.
    Rauch SL; Jenike MA
    Psychosomatics; 1993; 34(1):20-32. PubMed ID: 8426888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment of obsessive-compulsive disorder: a review of findings in the light of diagnostic and metric limitations.
    Towbin KE; Leckman JF; Cohen DJ
    Psychiatr Dev; 1987; 5(1):25-50. PubMed ID: 2885832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapy for social anxiety disorder (SAnD).
    Williams T; Hattingh CJ; Kariuki CM; Tromp SA; van Balkom AJ; Ipser JC; Stein DJ
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001206. PubMed ID: 29048739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.